Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II vididencel combination study with oral azacitidine as the current standard of care in AML maintenance

Next Previous
Trial Profile

A phase II vididencel combination study with oral azacitidine as the current standard of care in AML maintenance

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Vididencel (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms CADENCE

Most Recent Events

  • 15 Mar 2024 According to a Mendus media release, company will receive proceeds of up to approximately SEK 90.6 million and company intends to use proceeds from the Warrants to finance the continuation of its operations and extension of cash runway to Q3 2025, including futility analysis of the oral azacitidine combination trial with vididencel as a first step towards pivotal-stage trial design.
  • 12 Mar 2024 According to a Mendus media release, the recruitment for the AMLM22-CADENCE trial is expected to commence in April 2024.
  • 14 Feb 2024 According to a Mendus media release, based on the ADVANCE II data and data from the first stage of the CADENCE trial, Mendus expects to be in a position to engage in a global registration path for vididencel in 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top